EquiSeq
EquiSeq is a privately-held equine genetic testing company that sells a six-variant Myopathy Panel DNA test direct to horse owners, breeders, and veterinarians for $299, with patented technology licensed to Generatio GmbH in Europe.
- Company typePrivate
- Founded2015
- HeadquartersAlbuquerque, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What EquiSeq does
EquiSeq, Inc. is a privately-held biotechnology company founded in February 2015 in Albuquerque, New Mexico, that develops and sells DNA tests for inherited equine muscle diseases. Its flagship product, the Myopathy Panel (also called the MIM Panel or PSSM2/MFM Test), analyzes six genetic variants — P2 (MYOT), P3 (FLNC), P4 (MYOZ3), P8 (PYROXD1), K1 (COL6A3), and Px (CACNA2D3) — to identify horses at risk for Muscle Integrity Myopathy (MIM), also known as PSSM2 or Myofibrillar Myopathy (MFM), before clinical symptoms appear. In the United States, the test is run using allele-specific PCR on hair or blood samples collected via veterinarians, with results returned quickly enough to inform pre-purchase examinations; the company's patented technology has been in commercial use since 2017, with more than 15,000 horses tested to date.
The company's underlying technology platform is protected by 37 patents held by team members across the United States, Australia, New Zealand, South Africa, the European Union, the United Kingdom, and Canada, including two US patents issued in September and December 2025. EquiSeq has built a six-university scientific validation network (UCSD, Monash, Texas A&M, University of Minnesota, Université de Strasbourg, and Generatio GmbH) to support product credibility. The business model is primarily direct-to-consumer e-commerce via equiseq.com, with a single Myopathy Panel priced at $299 and a 20% bulk discount ($239 per test) available for orders of 10 or more panels; the company also licenses its patented technology to Generatio GmbH in Germany, which delivers a broader Illumina BeadArray-based test to European customers. Customers are segmented into horse owners (pre-purchase exams, health management), breeders (reducing inherited disease incidence in foals), and veterinarians (diagnostic support), with marketing executed through a content-led, education-driven approach including webinars ("Decoding Horse Health"), a YouTube channel, blog content, and earned media.
EquiSeq firmographics
Firmographics- Name
- EquiSeq
- Legal name
- EquiSeq Inc.
- Website
- https://equiseq.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EquiSeq is a privately-held equine genetic testing company that sells a six-variant Myopathy Panel DNA test direct to horse owners, breeders, and veterinarians for $299, with patented technology licensed to Generatio GmbH in Europe.
- Ownership category
- akta.pro rank
EquiSeq industry classification
Industry- Product category
- Equine Genetic Testing
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Veterinary Services (54194)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Reference Laboratory Testing (Clinical Pathology & Chemistry) (HLAMADAA)
Keywords
Where EquiSeq is headquartered
LocationHeadquarters
- HQ city
- Albuquerque
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EquiSeq business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Direct DNA Test Sales: EquiSeq sells its Myopathy Panel DNA test directly to horse owners, breeders, and veterinarians through its e-commerce website. The test is a one-time purchase with no recurring fees for the consumer. Bulk discounts are available for orders of 10 or more tests.
- Technology Licensing: EquiSeq licenses its patented DNA testing technology to Generatio GmbH in Germany, which provides equine genetic testing for Europe using Illumina BeadArray technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Myopathy Panel - Single Test |
| Unit Pricing | Pay-as-you-go | Myopathy Panel - Bulk Orders (10+) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
EquiSeq product offering
Product offeringCore offering
EquiSeq sells a patented equine DNA test — the Myopathy Panel — that analyzes six genetic variants (P2/MYOT, P3/FLNC, P4/MYOZ3, P8/PYROXD1, K1/COL6A3, Px/CACNA2D3) to identify horses at risk for Muscle Integrity Myopathy (MIM), PSSM2, and Myofibrillar Myopathy (MFM). Samples are collected non-invasively from hair or blood and processed via allele-specific PCR in the US, with the same patented technology licensed to Generatio GmbH for European delivery on Illumina BeadArray.
Product overview
EquiSeq offers a unified genetic testing product centered on the Myopathy Panel (also called MIM Panel or PSSM2/MFM Test), which analyzes six genetic variants (P2, P3, P4, P8, K1, Px) associated with equine muscle diseases including PSSM2, MIM, and MFM. The core product is sold directly to US consumers via allele-specific PCR technology at $299, with a bulk discount available for 10+ tests. The technology is also licensed to Generatio GmbH in Germany, which uses Illumina BeadArray for European customers. The test requires only a hair or blood sample and is designed for pre-purchase exams, breeding decisions, and health management.
Differentiator
Problem solved
Functional benefit
Products and services
- Myopathy Panel (EquiSeq MIM Panel) Comprehensive genetic test panel analyzing six equine muscle disease variants (P2/MYOT, P3/FLNC, P4/MYOZ3, P8/PYROXD1, K1/COL6A3, Px/CACNA2D3) to identify horses at risk for Muscle Integrity Myopathy (MIM), also known as PSSM2 or Myofibrillar Myopathy (MFM), before symptoms appear. Targeted at horse owners and breeders.
- US DNA Test (Allele-specific PCR) Genetic testing service for US customers using allele-specific PCR technology. Priced at $299 per test, includes P2, P3, P4, Px, P8, and K1 variant analysis. Hair samples are submitted through the customer's veterinarian; turnaround time is fast enough to support pre-purchase exam decisions.
- Licensed Technology (Generatio GmbH Europe) EquiSeq's patented DNA testing technology licensed to Generatio GmbH in Germany, which provides equine genetic testing for European customers using Illumina BeadArray technology (comprehensive test covering tens of thousands of variants).
Quantifiable outcome
- Over 15,000 horses tested commercially since 2017
- +2 more outcomes
Companies that use EquiSeq
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
EquiSeq technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
EquiSeq partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Generatio GmbHcoreEquiSeq licensed its patented DNA testing technology to Generatio GmbH, a German company that provides equine genetic testing for Europe. Generatio uses Illumina BeadArray technology (comprehensive test for tens of thousands of variants), contrasting with EquiSeq's allele-specific PCR approach in the US.
- University of California, San Diego (UCSD)coreUCSD researchers including G. Diane Shelton DVM, PhD collaborate with EquiSeq to validate product quality and efficacy. The Bryson-Richardson Lab at UCSD studies neuromuscular biology relevant to EquiSeq's muscle disease testing.
- Monash UniversitycoreMonash University researchers Robert Bryson-Richardson, PhD and Rita Serrano, PhD collaborate with EquiSeq. The Bryson-Richardson Lab focuses on muscle biology research relevant to equine neuromuscular disease.
- Texas A&M UniversitycoreTexas A&M College of Veterinary Medicine & Biomedical Sciences researchers, including Rytis Juras DVM, PhD, collaborate with EquiSeq on equine genetics research and product validation.
- University of MinnesotacoreUniversity of Minnesota Equine Genetics and Genomics Laboratory researchers Molly McCue DVM, PhD, Nicole Tate, PhD, and Kirsten Dimmler collaborate with EquiSeq. Dr. McCue supervised the dissertation research on Recurrent Exertional Rhabdomyolysis (RER) that contributed to EquiSeq's scientific foundation.
- Université de StrasbourgcoreResearchers Sylvie Friant, PhD and Bruno Rinaldi, PhD at Université de Strasbourg collaborate with EquiSeq on intracellular trafficking and lipid signaling research relevant to equine muscle biology.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
EquiSeq competitors and assessment
Company assessmentDirect peers
- Animal Genetics Inc: US-based genetic testing laboratory offering parentage verification, disease, and coat-color DNA tests for horses and other animals. Direct competitor in equine molecular diagnostics with overlapping veterinary-channel GTM.
- Etalon Diagnostics: Equine-focused genetic diagnostics company providing DNA-based parentage, disease, and trait testing for horses. Closely comparable product scope and end-customer (breeders, owners, registries) within the same niche.
- Generatio GmbH: German genetic testing laboratory and EquiSeq's exclusive European licensee, providing equivalent equine DNA testing through Illumina BeadArray technology. The closest one-to-one competitor in the EU market for the same clinical use case.
- UC Davis Veterinary Genetics Laboratory: Established academic reference laboratory within the UC Davis School of Veterinary Medicine offering hereditary disease and parentage genetic testing for horses. A legacy direct competitor with broader test menu and academic reputation.
Broad incumbents
- Antech Diagnostics: Veterinary diagnostics reference laboratory owned by Mars Petcare, serving thousands of North American vet clinics. Significant channel leverage that could be redirected into equine genetic testing if commercially warranted.
- Zoetis: Largest global animal health company offering diagnostics, vaccines, and pharmaceuticals. Operates Vetscan diagnostics in-clinic platforms that could extend into equine genetic testing and compete through embedded vet workflows.
- Neogen Corporation: Large agricultural genomics and animal safety company operating across food safety, animal genomics, and diagnostics. Provides equine genetic testing as part of a much broader portfolio with the scale to defend distribution channels.
- Wisdom Panel: Established direct-to-consumer pet genetic testing service owned by Mars, covering dogs and cats. Demonstrates how an animal-genetics DTC brand can scale into a mass-market testing business with strong brand recognition.
- Idexx Laboratories: Major veterinary diagnostics company with broad clinical laboratory services and in-clinic instruments used by companion-animal and equine practices. Could expand into equine genetic testing through existing vet relationships and capital.
Emerging players
- Embark Veterinary: Direct-to-consumer canine genetic testing company with comparable business model — comprehensive panel, university research partnerships, and breed-specific insights. A useful reference for how a small-team DTC animal genetics company can scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
EquiSeq social profiles
Digital presenceEquiSeq financial estimates
Financial estimateRevenue estimate
Valuation estimate
EquiSeq leadership team
Management profileNumber of profiles
Profiles16 records
EquiSeq funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EquiSeq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EquiSeq
What does EquiSeq do?
EquiSeq sells a patented equine DNA test — the Myopathy Panel — that analyzes six genetic variants (P2/MYOT, P3/FLNC, P4/MYOZ3, P8/PYROXD1, K1/COL6A3, Px/CACNA2D3) to identify horses at risk for Muscle Integrity Myopathy (MIM), PSSM2, and Myofibrillar Myopathy (MFM). Samples are collected non-invasively from hair or blood and processed via allele-specific PCR in the US, with the same patented technology licensed to Generatio GmbH for European delivery on Illumina BeadArray.
Is EquiSeq a public or private company?
EquiSeq is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EquiSeq founded?
EquiSeq was founded in 2015. It employs 1 to 10 people.
Where is EquiSeq based?
EquiSeq is headquartered in Albuquerque, United States, in the North America region.
How does EquiSeq make money?
Two revenue lines are on record. Direct DNA Test Sales are the primary driver. The others are technology Licensing.
Who are EquiSeq's main competitors?
Direct peers on record are Animal Genetics Inc, Etalon Diagnostics, Generatio GmbH and UC Davis Veterinary Genetics Laboratory. Broad incumbents are Antech Diagnostics, Zoetis, Neogen Corporation, Wisdom Panel and Idexx Laboratories. Embark Veterinary is listed as an emerging player.
Does EquiSeq have an API?
No public API is recorded for EquiSeq.
What industry is EquiSeq in?
EquiSeq's product category is Equine Genetic Testing. Its primary akta.pro industry code is HLAMADAE, Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 2835.